Market Closed -
Nasdaq
04:00:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
2.71
USD
|
-4.58%
|
|
+2.26%
|
-16.87%
|
Fiscal Period: December |
2023
|
---|
Capitalization
1 |
19.87
|
Enterprise Value (EV)
1 |
17.24
|
P/E ratio
|
-3.68
x
|
Yield
|
-
|
Capitalization / Revenue
|
305,669,831
x
|
EV / Revenue
|
265,289,369
x
|
EV / EBITDA
|
-3,213,652
x
|
EV / FCF
|
-4,099,434
x
|
FCF Yield
|
-0%
|
Price to Book
|
7.66
x
|
Nbr of stocks (in thousands)
|
6,095
|
Reference price
2 |
3.260
|
Announcement Date
|
3/29/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
0.01
|
0.065
|
EBITDA
|
-
|
-
|
-2.455
|
-5.366
|
EBIT
1 |
-0.3472
|
-0.5554
|
-2.456
|
-5.368
|
Operating Margin
|
-
|
-
|
-24,558.01%
|
-8,257.73%
|
Earnings before Tax (EBT)
1 |
-0.3417
|
-0.5858
|
-2.802
|
-5.356
|
Net income
1 |
-0.3417
|
-0.5858
|
-2.802
|
-5.356
|
Net margin
|
-
|
-
|
-28,024.87%
|
-8,239.8%
|
EPS
2 |
-0.0964
|
-0.1568
|
-0.6989
|
-0.8853
|
Free Cash Flow
|
-
|
-0.1635
|
0.096
|
-4.206
|
FCF margin
|
-
|
-
|
960.33%
|
-6,471.37%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/10/22
|
6/10/22
|
4/25/23
|
3/29/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.2
|
0.58
|
1.52
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
2.62
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.6196
x
|
-
|
Free Cash Flow
|
-
|
-0.16
|
0.1
|
-4.21
|
ROE (net income / shareholders' equity)
|
-
|
75.6%
|
138%
|
2,303%
|
ROA (Net income/ Total Assets)
|
-
|
-4,618%
|
-3,396%
|
-235%
|
Assets
1 |
-
|
0.0127
|
0.0825
|
2.281
|
Book Value Per Share
2 |
-0.1500
|
-0.2600
|
-0.7600
|
0.4300
|
Cash Flow per Share
2 |
0
|
0
|
0.0100
|
0.4300
|
Capex
|
-
|
-
|
0.01
|
-
|
Capex / Sales
|
-
|
-
|
87.44%
|
-
|
Announcement Date
|
6/10/22
|
6/10/22
|
4/25/23
|
3/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -16.87% | 22.3M | | +55.55% | 59.34B | | +43.17% | 40.24B | | -4.71% | 39.88B | | -5.56% | 28.55B | | +13.76% | 27.26B | | -22.00% | 19.23B | | +31.50% | 12.61B | | +2.16% | 12.49B | | +25.70% | 12.28B |
Other Biotechnology & Medical Research
|